RE:RE:RE:RE:RE:RE:I have complaintsYou have to admit anything in China will equate to higher risk. If not you are completely ignoring political risk and regulatory risks. Maybe high potential reward can justify such high risk. Why can't thtx get a deal in the U.S first?
Personally I stay away form investing in chinese companies as I have been burnt in the past so I don't have high level of trust.
If they do go that route I hope you are correct and it is all puppy dogs and rainbows! :-)
qwerty22 wrote: I don't get the negativity around China deals. It's not true that Pharma don't do deals in China. They do exactly the same deals they do in the West. The in-license drugs and tech from Chinese developer. Seagen just did a multi-billion dollar one for ADCs. I haven't crunched numbers but my impression of biotech out-licensing for the China region is they are often very lucrative deals with large upfront payments. I'd love to see a China deal for thtx.
stockman75 wrote: It seems like a bit of a desparate move to risk a deal with a Chinese company? If they really have something in cancer why not wait it out. I don't think it is worth pushing on that angle just so we can fund Nash 6 months earlier. Just me but I am not too optimistic about Nash based on the failure of so many others. Hopefully I am wrong about that.
CreatingApe wrote:
I'm sure there are some very lucrative deals being done with chinese companies no? It's an absolutely massive market. If we know how to cover our asses on IP'S a partnership with reputable chinese companies could pay massive dividends. Or does the risk outweigh the reward? I really dont know..